A Simple LC-MS/MS Method for the Quantification of PDA-66 in Human Plasma

Rico Schwarz, Elisabeth R.D. Seiler, Sina Sender, Anahit Pews-Davtyan, Hugo Murua Escobar, Dietmar Zechner, Matthias Beller, Christian Junghanß, Burkhard Hinz

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


The treatment of cancer is one of the most important pharmacotherapeutic challenges. To this end, chemotherapy has for some time been complemented by targeted therapies against specific structures. PDA-66, a structural analogue of the inhibitor of serine–threonine kinase glycogen synthase kinase 3β SB216763, has shown preclinical antitumour effects in various cell lines, with the key pathways of its anticancer activity being cell cycle modulation, DNA replication and p53 signalling. For the monitoring of anticancer drug treatment in the context of therapeutic drug monitoring, the determination of plasma concentrations is essential, for which an LC-MS/MS method is particularly suitable. In the present study, a sensitive LC-MS/MS method for the quantification of the potential anticancer drug PDA-66 in human plasma with a lower limit of quantification of 2.5 nM is presented. The method was successfully validated and tested for the determination of PDA-66 in mouse plasma and sera.

Original languageEnglish
Article number974
Issue number3
StatePublished - 1 Feb 2022
Externally publishedYes


  • Human plasma
  • LC-MS/MS
  • Liquid–liquid extraction
  • PDA-66
  • Validation


Dive into the research topics of 'A Simple LC-MS/MS Method for the Quantification of PDA-66 in Human Plasma'. Together they form a unique fingerprint.

Cite this